Elicio Therapeutics reported a Q3 2025 net loss of $10.1 million, a sharp improvement from the $18.8 million loss recorded in Q3 2024. Earnings per share were $0.60, beating the consensus estimate of $0.62 by $0.02. Research and development costs fell to $5.0 million from $7.2 million, while general and administrative expenses were $3.0 million, slightly lower than the $3.1 million reported a year earlier. Cash and cash equivalents stood at $20.6 million, giving the company a runway that now extends through the second quarter of 2026 rather than the first quarter as previously stated.
The EPS beat was driven by disciplined cost management and a stronger-than‑expected clinical profile. Lower R&D spending reflects the fact that more patients in the Phase 2 AMPLIFY‑7P study have progressed through the trial, reducing the need for additional investigational activities. General and administrative costs were trimmed by $0.1 million through reduced consulting fees and a modest decline in corporate overhead. Together, these savings narrowed the net loss and lifted earnings to a positive figure that exceeded analyst expectations.
The company’s clinical momentum is underscored by a positive recommendation from its Independent Data Monitoring Committee, which advised continuing the Phase 2 study to final analysis. Fewer disease progressions and deaths than projected have bolstered confidence in the study’s event‑driven primary disease‑free survival endpoint, which is expected to be analyzed in the first half of 2026. Management highlighted that the early data suggest a favorable impact on DFS, reinforcing the platform’s potential in KRAS‑mutant cancers.
CEO and CFO comments emphasized the company’s optimism: “We are encouraged to see fewer disease progressions and deaths in the Phase 2 AMPLIFY‑7P study than originally projected in our statistical modeling. This may reflect a favorable impact on DFS,” said the CEO. “Importantly, we believe our current cash position will allow us to reach this critical catalyst and beyond as we continue advancing ELI‑002 7P toward its potential to meaningfully improve outcomes for patients with pancreatic ductal adenocarcinoma.”
Analysts had a consensus EPS estimate of $‑0.62 for the quarter, so the $0.60 result represents a modest beat of $0.02. Market reaction to the earnings was muted, with no significant change in investor sentiment reported, but the company’s extended cash runway and positive clinical signals have reinforced confidence in its near‑term strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.